GWN Securities Inc. Takes $1.63 Million Position in Pfizer Inc. (NYSE:PFE)

GWN Securities Inc. bought a new stake in shares of Pfizer Inc. (NYSE:PFE) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 62,548 shares of the biopharmaceutical company’s stock, valued at approximately $1,633,000.

Several other large investors have also recently made changes to their positions in PFE. Swedbank AB lifted its holdings in shares of Pfizer by 0.7% during the third quarter. Swedbank AB now owns 5,745,831 shares of the biopharmaceutical company’s stock valued at $166,284,000 after purchasing an additional 37,636 shares during the last quarter. United Bank raised its holdings in Pfizer by 3.7% in the 3rd quarter. United Bank now owns 35,599 shares of the biopharmaceutical company’s stock worth $1,030,000 after acquiring an additional 1,277 shares during the last quarter. GSA Capital Partners LLP raised its holdings in Pfizer by 87.6% in the 3rd quarter. GSA Capital Partners LLP now owns 32,786 shares of the biopharmaceutical company’s stock worth $949,000 after acquiring an additional 15,310 shares during the last quarter. Curi RMB Capital LLC raised its holdings in Pfizer by 4.7% in the 3rd quarter. Curi RMB Capital LLC now owns 55,770 shares of the biopharmaceutical company’s stock worth $1,614,000 after acquiring an additional 2,487 shares during the last quarter. Finally, CIBC Asset Management Inc raised its holdings in Pfizer by 6.2% in the 3rd quarter. CIBC Asset Management Inc now owns 1,065,338 shares of the biopharmaceutical company’s stock worth $30,831,000 after acquiring an additional 61,988 shares during the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Trading Up 0.5 %

Shares of PFE stock opened at $25.74 on Friday. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54. The firm has a fifty day moving average price of $26.24 and a 200-day moving average price of $27.13. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The company has a market cap of $145.85 billion, a price-to-earnings ratio of 18.25, a PEG ratio of 0.64 and a beta of 0.61.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. During the same quarter in the previous year, the firm posted $0.10 EPS. The company’s revenue for the quarter was up 24.7% compared to the same quarter last year. As a group, equities analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Insider Activity at Pfizer

In other news, Director Ronald E. Blaylock bought 19,457 shares of the stock in a transaction that occurred on Thursday, February 13th. The shares were bought at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the purchase, the director now owns 27,707 shares in the company, valued at $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this link. 0.06% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on PFE shares. UBS Group decreased their price objective on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a report on Wednesday, January 8th. Truist Financial decreased their price objective on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, December 18th. Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a report on Monday, March 10th. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a research report on Wednesday. Finally, StockNews.com downgraded shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 20th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and three have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $31.92.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.